Stoke Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Stoke Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $45.1. The average 1-year stock price forecast is 50.33% higher than the current stock price, while the lowest is $35 (+16.67%) and the highest is $60 (+100.00%).

Price Target: $45.1 (+50.33%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$35	$45.1	$40	$60
Change	+16.67%	+50.33%	+33.33%	+100.00%

* Price targets were last updated on May 11, 2026.

Analyst Ratings

The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	9	11	11	11	11	11
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	12	12	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Marc Goodman Leerink Partners	Leerink Partners	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 2, 2026
Thomas Shrader BTIG	BTIG	Buy Maintains $39	Buy	Maintains	$39	+30.00%	May 11, 2026
Ananda Ghosh H.C. Wainwright	H.C. Wainwright	Buy Maintains $50	Buy	Maintains	$50	+66.67%	May 8, 2026
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Buy Maintains $60	Buy	Maintains	$60	+100.00%	May 8, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $38	Buy	Maintains	$38	+26.67%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

26.24M

from 184.42M

-85.77%

from 184.42M

Revenue Next Year

46.23M

from 26.24M

76.21%

from 26.24M

EPS This Year

-3.25

from -0.12

EPS Next Year

-3.08

from -3.25

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	12.41M	8.78M	36.56M	184.42M	26.24M
Revenue Growth	-	-	-29.22%	316.34%	404.50%	-85.77%
Gross Profit	-	12.41M	8.78M	36.56M	184.42M	26.24M
Gross Margin	-	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Income	-86.07M	-104.36M	-114.77M	-101.37M	-20.59M	-222.16M
Net Income	-85.81M	-101.07M	-104.70M	-88.98M	-6.89M	-210.14M
EPS	-	-	-	-	-0.12	-3.25
Free Cash Flow	-34.78M	-36.15M	-45.10M	-26.46M	33.02M	-206.37M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	58.7M
Avg	26.2M
Low	6.2M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-68.2%
Avg	-85.8%
Low	-96.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-3.25
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-